ADISCTI (AdisInsight Trials, formerly Adis Clinical Trials Insight) THE CHOICE OF PATENT EXPERTS

Subject Coverage	and the results pub updated weekly wi global literature, ar Highlights of the re	olished from th the latest ad presented cords includ	these trials. Profiles information posted of in conference abstract.	files of pharmaceutical clinical trials are written by Adis experts and on clinical trial registries, published in racts from around the world. ubject enrollment, study centers, afety.
File Type	Bibliographic, Full t	ext		
Features	Alerts (SDIs)	Weekly		
	CAS Registry Number® Identifiers			
	Keep & Share		Page Images	
	Learning Database		SLART	
Record Content	 Bibliographic and indexing information Profiles contain disease studied, drug dosage information, subject inclusion/exclusion criteria, study progress, study endpoints, reported efficacy and safety. 			
File Size	More than 211,000 records (01/22)			
Coverage	1998-present			
Updates	Weekly			
Language	English			
Database Producer	Springer Nature Sv Copyright Holder	vitzerland A	G	
	Contact Springer C Email: onlineservic Phone: +49 6221: +1 800 777	<u>e@springer</u> 345 4303 (E	.com	

Sources

- Direct contact with companies involved with research and development
- Major clinical trial registries including clinicaltrials.gov, eudraCT, and WHO
- 1,700 biomedical and medical journals
- International meetings and conferences
- Company annual reports
- News services
- Press releases

User Aids

- Online Helps (HELP DIRECTORY lists all help messages available)
- STNGUIDE

Clusters

- ADISBASES
- ALLBIB
- AUTHORS
- BIOSCIENCE
- CORPSOURCE
- FULLTEXT
- HEALTH
- MEDICINE
- PHARMACOLOGY
- TOXICOLOGY

STN Database Clusters information (PDF).

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*).

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the title (TI), controlled term (CT), text (TX), and evaluation (EVAL) fields)	None (or /BI)	S PHARMACOKINETICS S QUALITY OF LIFE S RESIST? (L) NEGATIVE S VACCINE# (S) USE S PATIENT-CONTROLLED S ?DIABET(L)?THERAP?	CT, EVAL, TI, TX
Accession Number ADIS Last Update Date (2) ADIS Record Creation Date (2) Author	/AN /DUP /DED /AU	S 2006:1005/AN S 20051004/DUP S 20051004/DED S JENSEN P?/AU S JENSEN, P?/AU	AN DUP DED AU
Controlled Term	/CT	S THERAPEUTIC EQUIVALENCE/CT S CORONARY SPASM, TREATMENT/CT	СТ
Controlled Word	/CW	S (ACICLOVIR (L) ACTIVITY)/CW S (INHIBITORS (S) ANTIMICROBIAL)/CW	СТ
Corporate Source (organization name and location) (1)	/CS	S (VETERANS AFFAIRS AND ALABAMA)/CS	cs
Document Number Document Type (text)	/DN /DT (or /TC)	S 801032402/DN S BEST EVIDENCE/DT	DN DT
Entry Date (2) Evaluation (3,4)	/ED /EVAL	S L1 AND ED>=20051100 S CONTROLS/EVAL S MEDIA RELEASE/EVAL	ED EVAL
Field Availability International Standard (Document) Number	/FA /ISN	S L3 AND SIDE/FA S 8750-2836/ISN	Not displayed ISN, SO
Journal Title (contains full and abbreviated journal titles)	/JT	S REGION ANESTH/JT S REGIONAL ANESTHESIA/JT	JT, JTA, JTF, SO
Language (code and text)	/LA	S L2 AND ENGLISH/LA S L2 AND EN/LA	LA
Number of Patients (2,3) Ongoing Trial Comment Other Source	/PNO /OT /OS	S PNO<=100 S TRANSDERMAL?/OT S 2006000118/OS S ADISINSIGHT/OS	PNO OT OS
Publication Date (2) Publication Year (2) Reference (1)	/PD /PY /RE	S ADISINSIGHT/OS S JUN 1-30 2005/PD S 2004/PY S EPILEPSY DISORDERS/RE	PD, SO PY, SO RE
Source (contains journal title, publication date, ISSN, and collation information (volume, issue, and page numbers))	/SO	S (BIOLO? AND BULL? AND VOL 20)/SO	SO
Title *	/TI	S (VITRO AND ACTIVITY)/TI S ?MALARIA?/TI S (KETOLIDE (S) ANTIMICROBIAL)/TI	ТІ
Update Date (2) Word Count (2,3)	/UP /WC	S L7 AND 20021100-20021200/UP S L1 AND WC<200	ED WC

ADISCTI

- (1) Implied (S) proximity is available in this field.
- (2) Numeric search field that may be searched using numeric operators or ranges.

- (3) This field is available only in the SUMMARY file segment.
 (4) See HELP SCORE for more information.
 (5) This score is only available in selected records published in November 2010 and earlier.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Format	Content	Examples
AN (1)	Accession Number	D L4 1-4 AN
AU	Author	D AU CS
CS	Corporate Source	D CS 1,3-5
CT (1)	Controlled Term (Drug Descriptors, Disease Descriptors, and Other Descriptors)	D CT 5-10
DED	ADIS Record Creation Date	D DED
DN	Document Number	D 1-3,7,8 DN
DT (TC)	Document Type	D DT
DUP	ADIS Last Update Date	D DUP
ED	Entry Date	D ED
EVAL (2)	Evaluation (Positive Features, Negative Features, Adis Comment, and Adis Evaluation)	D EVAL 15
ISN	International Standard (Document) Number	D ISN
JT (3)	Journal Title, Full and Abbreviated	D JT
JTA (3)	Journal Title, Abbreviated	D JTA 2
JTF (3)	Journal Title, Full	D JTf
LA	Language	D LA
OS	Other Source	D OS
OT	Ongoing Trial Comment	OT
PD (3)	Publication Date	D PD
PNO (1,2)	Number of Patients	D PNO
PY (3)	Publication Year	D PY
RE	Reference	D RE
SO	Source	D SO
TI (1)	Title	D TI
TX (2)	Text (Global Study Outcome (Efficacy, Tolerability, Pharmacoeconomics), Study Message (Efficacy, Tolerability), Results Highlights (Efficacy, Tolerability), Purpose, Author Comments, Study Details (Design, Control, Phase, Methodology, EndPoints, Companies) Subject Details (Type, No., Age, Sex, Location, Disease, Characteristics), Drug, Drug Table (Drug/Treatment, Dose, Route, Frequency, Duration), Results (Results Table), Case Details (Toxicity, Dechallenge, Outcome, Claimed Association, Key Details), and Age Key)	DTX
UP	Update Date	D UP
WC (1,2)	Word Count	D WC
ALL	AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED, EVAL, TX, PNO, CT	D ALL
BIB CBIB	AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED BIB in compressed format	D 2 L5 BIB D CBIB

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
DALL IALL IBIB IND (1) SCAN (1,4) TEXT (2) TRIAL (TRI, SAM) (1)	ALL, delimited for post processing ALL, indented with text labels BIB, indented with text labels PNO, CT TI, PNO, CT (random display, no answer numbers) EVAL, TX, PNO TI, PNO, CT	D DALL D IALL D IBIB D IND D SCAN D TEXT D TRIAL TOTAL
HIT KWIC OCC (1)	Fields containing hit terms Hit terms with 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they occur	D HIT D KWIC NOH D OCC

- (1) No online display fee for this format.
- (2) This field is available only in the SUMMARY file segment.
- (3) Custom display format only.
- (4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Accession Number	AN	Υ	N
ADIS Last Record Update	DUP	Υ	Υ
ADIS Record Creation Date	DED	Υ	Υ
Author	AU	Υ	Υ
Citation	CIT	Y (2,3)	N
Controlled Term	CT	Υ	N
Corporate Source	CS	Υ	Υ
Document Number	DN	Υ	Υ
Document Type	DT	Υ	Υ
Entry date	ED	Υ	Υ
Evaluation (4)	EVAL	Υ	N
File Segment	FS	Υ	Y
International Standard (Document) Number	ISN	Υ	Y
Journal Title	JT	Y (5)	Υ
Journal Title, Abbreviated	JTA	Y (6)	Y
Journal Title, Full	JTF	Y (6)	Y
Language	LA	Υ	Y
Number of Patients (4)	PNO	Υ	Y
Occurrence Count of Hit Terms	OCC	N	Y
Ongoing Trial Comment	OT	Υ	N
Other Source	os	Υ	N

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Publication Date	PD	Υ	Υ
Publication Year	PY	Υ	Y
Reference	RE	Υ	Y
Text (4)	TX	Y (7)	N
Title	TI	Y (default)	Υ
Treatment Code	TC	Υ	Υ
Update Date	UP	Υ	Υ
Word Count (4)	WC	N	Υ

- (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CT.
- (2) SELECT HIT and ANALYZE HIT are not valid with this field.
- (3) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms created by SELECT.
- (4) This field is available only in the SUMMARY file segment.
- (5) Selects or analyzes full and abbreviated journal titles with /JT appended to the terms created by SELECT.
- (6) Appends /JT to the terms created by SELECT.
- (7) Appends /BI to the terms created by SELECT.

Full-Text Browsing

User Request	Example	System Response
DISPLAY BROWSE	=> DISPLAY BROWSE ENTER (L1) OR L#:. ENTER (DIS), ANSWER NUMBERS, OR END:	NOVICE version
D BRO	=> D BRO L1	EXPERT version
Answer number(s)	:1-3	display answers 1, 2, and 3 in default format
Answer number(s) and format	:4 HIT	display answer 4 in HIT format
Format only	:TI TX	display title and text of last answer displayed
Change default format	:*KWIC	change default to KWIC no answer displayed
Forward n fields	:F3	move forward 3 fields
Backward n fields	:B1	move backward 1 field
Search forward for character string	:S BONE MARROW	search forward within record for 'bone marrow'
Search backward for character string	:S- NAUSEA	search backward within record for 'nausea'
End DISPLAY BROWSE	:END	exit DISPLAY BROWSE and return
	=>	to => prompt

Sample Records

DISPLAY IALL

ACCESSION NUMBER: 2006: 18471 ADI SCTI

DOCUMENT NUMBER: 700009023

TITLE: ADIS TITLE: Effectiveness of an NK1 Antagonist in

PTSD.

DOCUMENT TYPE: ADIS REC. CREATED: ADIS LAST UPDATE: Ongoi ng Tri al 26 Nov 2005 4 Mar 2014

REFERENCE: Anxiety Disorders; Mental Disorders

1.) Clinical Trials. gov: US National Institutes of

Heal th

LANGUAGE: Engl i sh WORD COUNT: 283

ADISINSIGHT 1998005744 OTHER SOURCE: **ENTRY DATE:**

ONGOING TRIAL COMNT:

Entered STN: 12 Jun 2006
Last Updated on STN: 7 Mar 2014
Ongoing Trial Comment: This trial is entitled
"Effectiveness of an NK1 Antagonist [vofopitant] in
PTSD [post-traumatic stress disorder]". The primary outcome is the change in 17-item total severity

Clinician Administered PTSD Scale.

TEXT - Subject Details:

Planned No: 47

No: 64

Location: USA

Disease: Post-traumatic-stress-disorders

Patient Inclusion: Aged 18-65 years; diagnosis of post-traumatic stress disorder for greater than or equal to 3 months; negative urine toxicology test; females willing to use an effective form of birth control throughout the study.

Patient Exclusion: Current diagnosis of schizophrenia or other psychotic disorder, current diagnosis of bipolar disorder or other psychiatric disorder except for depression secondary to post-traumatic stress disorder, participation in a clinical trial of a new drug during the previous 4 months or any other trial during the previous 3 months, current evidence or history of serious unstable medical illness or organic brain impairment, serious suicidal or homicidal risk, substance abuse within the last 90 days, use of effective psychiatric medications in the 2 weeks prior to screening or ***fluoxeti ne*** consumption of more than 4 drinks/day per in last 5 weeks, week if male or of more than 3 drinks/day per week if female, donation of blood within the previous month or intent to donate blood within one month of

completing the study, previous TEXT - Age Key: adult, elderly TEXT - Study Details: previous treatment with an NK1 antagonist.

Status: completed

Actual Start: August 2005 Planned Finish: November 2008 Actual Finish: November 2008

Design: double-blind, parallel, prospective, randomised

Phase: II

Endpoints: Assessment scale scores Biomarker levels (CSF levels of norepinephrine (NE) and NE metabolites.)

Brain volume (Hippocampal volume.) clinical Global Impressions scale

Clinical response rate Improvement in symptoms

Magnetic resonance imaging outcomes, Clinician Administered Post-Traumatic

Stress Disorder Scale

Study Center: Baylor School of Medicine, Mount Sinai School of Medicine, Emory University, National Institute of Mental Health Companies: GlaxoSmithKline

ADISCTI

ID: 700009023 (Clinical Trials Insight)
NCT00211861 (ClinicalTrials.gov: US National Institutes of Health)

U19MH069056()

64 NO. OF PATIENTS:

CONTROLLED TERM:

Drug Descriptors: Vofopitant Disease Descriptors: Post traumatic stress disorders, CONTROLLED TERM:

treatment

In North America CAS STN North America P.O. Box 3012 Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:

Phone: 800-753-4227 (North America) 614-447-3700 (worldwide) 614-447-3751

Email: help@cas.org Internet: www.cas.org

In Europe FIZ Karlsruhe STN Europe P.O. Box 2465 76012 Karlsruhe

76012 Name Germany Phone: +49-7247-808-555 Fax: +49-7247-808-259 Email: helpdesk@fiz-karlsruhe.de Internet: www.stn-international.com

In Japan JAICI (Japan Association for International Chemical Information) STN Japan Nakai Building

Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)

+81-3-5978-3600

support@jaici.or.jp (Technical Service) customer@jaici.or.jp (Customer Service)

Internet: www.jaici.or.jp